Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K -: Investigating P1′ substituents

被引：22
作者：
Altmann, E [1 ]
Green, J
Tintelnot-Blomley, M
机构：
[1] Novartis Pharma AG, Arthrit & Bone Metab Therapeut Area, CH-4002 Basel, Switzerland
[2] Novartis Pharma AG, Nervous Syst Therapeut Area, CH-4002 Basel, Switzerland
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 12期
关键词：
D O I：
10.1016/S0960-894X(03)00344-5
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Modeling, synthesis and in vitro activities of a series of arylaminoethyl amide based inhibitors of the cysteine protease cathepsin K are described. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：1997 / 2001
页数：5
相关论文
共 17 条
  • [1] Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors
    Altmann, E
    Renaud, J
    Green, J
    Farley, D
    Cutting, B
    Jahnke, W
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (12) : 2352 - 2354
  • [2] HUMAN CATHEPSIN O2, A NOVEL CYSTEINE PROTEASE HIGHLY EXPRESSED IN OSTEOCLASTOMAS AND OVARY MOLECULAR-CLONING, SEQUENCING AND TISSUE DISTRIBUTION
    BROMME, D
    OKAMOTO, K
    [J]. BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1995, 376 (06): : 379 - 384
  • [3] Cysteine proteases as therapeutic targets
    Brömme, D
    [J]. DRUG NEWS & PERSPECTIVES, 1999, 12 (02) : 73 - 82
  • [4] Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts
    Drake, FH
    Dodds, RA
    James, IE
    Connor, JR
    Debouck, C
    Richardson, S
    LeeRykaczewski, E
    Coleman, L
    Rieman, D
    Barthlow, R
    Hastings, G
    Gowen, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) : 12511 - 12516
  • [5] Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L
    Falgueyret, JP
    Oballa, RM
    Okamoto, O
    Wesolowski, G
    Aubin, Y
    Rydzewski, RM
    Prasit, P
    Riendeau, D
    Rodan, SB
    Percival, MD
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (01) : 94 - 104
  • [6] The collagenolytic activity of cathepsin K is unique among mammalian proteinases
    Garnero, P
    Borel, O
    Byrjalsen, I
    Ferreras, M
    Drake, FH
    McQueney, MS
    Foged, NT
    Delmas, PD
    Delaissé, JM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (48) : 32347 - 32352
  • [7] Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis
    Hou, WS
    Brömme, D
    Zhao, YM
    Mehler, E
    Dushey, C
    Weinstein, H
    Miranda, CS
    Fraga, C
    Greig, F
    Carey, J
    Rimoin, DL
    Desnick, RJ
    Gelb, BD
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (05) : 731 - 738
  • [8] Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis
    Huang, L
    Lee, A
    Ellman, JA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (03) : 676 - 684
  • [9] MOLECULAR-CLONING OF HUMAN CDNA FOR CATHEPSIN-K - NOVEL CYSTEINE PROTEINASE PREDOMINANTLY EXPRESSED IN BONE
    INAOKA, T
    BILBE, G
    ISHIBASHI, O
    TEZUKA, K
    KUMEGAWA, M
    KOKUBO, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 206 (01) : 89 - 96
  • [10] Protease inhibitors: Current status and future prospects
    Leung, D
    Abbenante, G
    Fairlie, DP
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (03) : 305 - 341
12